Literature DB >> 19764026

Genotype-phenotype correlations in VHL exon deletions.

Alisdair McNeill1, Eleanor Rattenberry, Richard Barber, Pip Killick, Fiona MacDonald, Eamonn R Maher.   

Abstract

Von Hippel-Lindau (VHL) syndrome is a dominantly inherited familial cancer syndrome caused by mutations in the VHL gene. VHL syndrome displays marked variation in expression and analysis of genotype-phenotype correlations have led to the concept of four subtypes of VHL syndrome (Types 1, 2A-C). Type 2 subtypes of VHL syndrome are characterized by the presence of pheochromocytoma and the three Type 2 subtypes are associated with differing risks of hemangioblastoma and renal cell carcinoma (RCC). Type 2 VHL syndrome is usually associated with surface missense mutations. Type 1 VHL syndrome is most commonly caused by germline exon deletions and truncating mutations and is characterized by susceptibility to hemangioblastomas and RCC but not pheochromocytoma. Recently, it has been suggested that large VHL gene deletions involving C3orf10 (HSPC300) might be associated with a low risk of RCC. We have reviewed the molecular and clinical characteristics of 127 individuals with germline VHL gene deletions. Large VHL gene deletions associated with a contiguous loss of C3orf10 were associated with a significantly lower lifetime risk of RCC than deletions that did not involve C3orf10. The risks of hemangioblastomas were similar in both groups. These results add to the growing body of evidence suggesting that patients with VHL syndrome caused by large VHL deletions that include C3orf10 may be designated as having a specific subtype (Type 1B) of the disorder.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19764026     DOI: 10.1002/ajmg.a.33023

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  27 in total

1.  Clinical utility gene card for: von Hippel-Lindau (VHL).

Authors:  Jochen Decker; Christine Neuhaus; Fiona Macdonald; Hiltrud Brauch; Eamonn R Maher
Journal:  Eur J Hum Genet       Date:  2013-08-28       Impact factor: 4.246

2.  A synonymous VHL variant in exon 2 confers susceptibility to familial pheochromocytoma and von Hippel-Lindau disease.

Authors:  Shahida K Flores; Ziming Cheng; Angela M Jasper; Keiko Natori; Takahiro Okamoto; Akiyo Tanabe; Koro Gotoh; Hirotaka Shibata; Akihiro Sakurai; Takuya Nakai; Xiaojing Wang; Magnus Zethoven; Shiva Balachander; Yuichi Aita; William Young; Siyuan Zheng; Kazuhiro Takekoshi; Eijiro Nakamura; Richard W Tothill; Ricardo C T Aguiar; Patricia L M Dahia
Journal:  J Clin Endocrinol Metab       Date:  2019-04-04       Impact factor: 5.958

3.  Genotype phenotype correlation in Asian Indian von Hippel-Lindau (VHL) syndrome patients with pheochromocytoma/paraganglioma.

Authors:  Nilesh Lomte; Sanjeet Kumar; Vijaya Sarathi; Reshma Pandit; Manjunath Goroshi; Swati Jadhav; Anurag R Lila; Tushar Bandgar; Nalini S Shah
Journal:  Fam Cancer       Date:  2018-07       Impact factor: 2.375

4.  The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms.

Authors:  Damla Olcaydu; Elisa Rumi; Ashot Harutyunyan; Francesco Passamonti; Daniela Pietra; Cristiana Pascutto; Tiina Berg; Roland Jäger; Emma Hammond; Mario Cazzola; Robert Kralovics
Journal:  Haematologica       Date:  2010-12-20       Impact factor: 9.941

Review 5.  Role of VHL gene mutation in human renal cell carcinoma.

Authors:  Wani Arjumand; Sarwat Sultana
Journal:  Tumour Biol       Date:  2011-11-29

6.  Clinical and molecular characterization of Brazilian families with von Hippel-Lindau disease: a need for delineating genotype-phenotype correlation.

Authors:  Israel Gomy; Greice Andreotti Molfetta; Ester de Andrade Barreto; Cristiane Ayres Ferreira; Dalila Luciola Zanette; José Cláudio Casali-da-Rocha; Wilson Araujo Silva
Journal:  Fam Cancer       Date:  2010-12       Impact factor: 2.375

7.  A novel missense mutation (N78D) in a family with von Hippel-Lindau disease with central nervous system haemangioblastomas, pancreatic and renal cysts.

Authors:  S Cingoz; R B van der Luijt; E Kurt; M Apaydin; I Akkol; Mihriban Heval Ozgen
Journal:  Fam Cancer       Date:  2013-03       Impact factor: 2.375

8.  Clinical and functional properties of novel VHL mutation (X214L) consistent with Type 2A phenotype and low risk of renal cell carcinoma.

Authors:  A D Sorrell; S Lee; C Stolle; J Ellenhorn; A Grix; W G Kaelin; J N Weitzel
Journal:  Clin Genet       Date:  2011-06       Impact factor: 4.438

Review 9.  Von Hippel-Lindau Disease.

Authors:  Jennifer J Findeis-Hosey; Kelly Q McMahon; Sarah K Findeis
Journal:  J Pediatr Genet       Date:  2016-04-04

Review 10.  Renal cancer in von Hippel-Lindau disease and related syndromes.

Authors:  Birke Bausch; Cordula Jilg; Sven Gläsker; Alexander Vortmeyer; Niklas Lützen; Alexandra Anton; Charis Eng; Hartmut P H Neumann
Journal:  Nat Rev Nephrol       Date:  2013-07-30       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.